SRTD raises €31.5M to advance cell-selective seRNA therapies
SRTD has closed a €31.5 million seed round led by Mérieux Equity Partners to advance preclinical development of a drug pipeline targeting cancer, autoimmune diseases...
This website uses cookies to improve your experience. We assume you agree, but you can opt out if you wish. Accept More Info